Cancers, Vol. 12, Pages 1761: Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
We describe the adaptive and innate components involved in the EOC immune response, including infiltrating tumor-specific T lymphocytes, B lymphocytes, and natural killer and myeloid cells. In addition, we highlight the rationale behind the use of EOC preclinical mouse models to assess resistance to immunotherapy, and we summarize the main preclinical studies that yielded anti-EOC immunotherapeutic strategies. Finally, we focus on major published or ongoing immunotherapy clinical trials concerning EOC.
Source: Cancers - Category: Cancer & Oncology Authors: Alejandra Martinez Jean-Pierre Delord Maha Ayyoub Christel Devaud Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Epithelial Cancer | Immunotherapy | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Skin Cancer | Study